Biohaven Pharmaceutical Holding Co Ltd - Asset Resilience Ratio
Biohaven Pharmaceutical Holding Co Ltd (BHVN) has an Asset Resilience Ratio of 16.03% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2025)
This chart shows how Biohaven Pharmaceutical Holding Co Ltd's Asset Resilience Ratio has changed over time. Check Biohaven Pharmaceutical Holding Co Ltd strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Biohaven Pharmaceutical Holding Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see BHVN market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $74.74 Million | 16.03% |
| Total Liquid Assets | $74.74 Million | 16.03% |
Asset Resilience Insights
- Good Liquidity Position: Biohaven Pharmaceutical Holding Co Ltd maintains a healthy 16.03% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Biohaven Pharmaceutical Holding Co Ltd Industry Peers by Asset Resilience Ratio
Compare Biohaven Pharmaceutical Holding Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 57.90% |
|
TELIX Pharmaceuticals Ltd
AU:TLX |
Biotechnology | 32.29% |
|
Inner Mongolia Furui Med Sci
SHE:300049 |
Biotechnology | 2.34% |
|
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX |
Biotechnology | 39.07% |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA |
Biotechnology | 0.00% |
Annual Asset Resilience Ratio for Biohaven Pharmaceutical Holding Co Ltd (2022–2025)
The table below shows the annual Asset Resilience Ratio data for Biohaven Pharmaceutical Holding Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 19.75% | $89.18 Million | $451.45 Million | -43.14pp |
| 2024-12-31 | 62.89% | $386.86 Million | $615.11 Million | +36.90pp |
| 2023-12-31 | 26.00% | $133.42 Million | $513.21 Million | -13.36pp |
| 2022-12-31 | 39.36% | $260.46 Million | $661.78 Million | -- |
About Biohaven Pharmaceutical Holding Co Ltd
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase… Read more